Stratec (SBS) Hisse Özeti
Stratec SE, iştirakleri ile birlikte Almanya, Avrupa Birliği ve uluslararası alanda in-vitro tanı ve yaşam bilimleri alanlarında otomasyon ve enstrümantasyon çözümleri tasarlamakta ve üretmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 2/6 |
SBS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Stratec SE Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | €17.24 |
| 52 Haftanın En Yüksek Seviyesi | €33.10 |
| 52 Haftanın En Düşük Seviyesi | €16.34 |
| Beta | 0.79 |
| 1 Aylık Değişim | -9.26% |
| 3 Aylık Değişim | -15.49% |
| 1 Yıllık Değişim | -34.57% |
| 3 Yıllık Değişim | -69.75% |
| 5 Yıllık Değişim | -85.54% |
| Halka arzdan bu yana değişim | 231.35% |
Son Haberler & Güncellemeler
Recent updates
Anlatı Güncellemesi • May 08
SBS: Lower Growth Assumptions Will Still Allow Future Upside Potential
The analyst fair value estimate for Stratec has been revised from about €26.00 to about €20.00, as analysts trim price targets and factor in lower revenue growth assumptions, softer profit margin expectations, and a higher implied future P/E, in line with recent target cuts from major banks. Analyst Commentary Recent Street research reflects a more cautious stance on Stratec, with price targets revised lower and expectations reset around revenue growth and profitability.
Anlatı Güncellemesi • Apr 21
SBS: Rebased Fair Value And 2025 Margin Guidance Will Define Upside Potential
The analyst price target for Stratec has been cut from about €44.96 to €34.00, as analysts factor in updated fair value, discount rate, growth, margin, and P/E assumptions following recent target revisions from major banks. Analyst Commentary Recent research suggests that while headline price targets for Stratec have come down, some bullish analysts still see potential upside at current levels.
Anlatı Güncellemesi • Apr 06
SBS: Future Upside Will Rely On Reset Margins And Higher P/E
Narrative Update on Stratec The updated analyst price target for Stratec is €28.46, reflecting recent target cuts of up to €12 from prior Street research as analysts factor in a slightly higher discount rate, modestly adjusted profit margin assumptions, and a higher future P/E multiple. Analyst Commentary Recent research commentary on Stratec has focused on recalibrating price targets while keeping an eye on execution risk and the valuation investors are being asked to pay.Anlatı Güncellemesi • Mar 23
SBS: Future Upside Will Depend On Repriced Earnings Power And Margins
Analysts have trimmed their average price target for Stratec by around €2.40, with recent cuts to €34 helping to explain a slightly lower fair value estimate and modestly softer assumptions for growth, margins and future P/E. Analyst Commentary Recent research revisions on Stratec point to a reset in expectations, with lower price targets feeding into updated views on valuation, execution risk and growth assumptions.Anlatı Güncellemesi • Mar 09
SBS: Higher Discount Rate And Index Removal Will Still Allow Future Upside
Narrative Update on Stratec The analyst price target for Stratec has been reduced by €1, as analysts reflect slightly adjusted assumptions around discount rates, revenue growth and profit margins in their updated models. Analyst Commentary Bearish analysts trimming their price targets, including the recent €1 reduction, are signaling a more cautious stance on Stratec.Anlatı Güncellemesi • Feb 22
SBS: Higher Discount Rate Will Still Allow Future Upside Potential
Analysts have reduced their price target on Stratec by €1 to €26, reflecting updated assumptions regarding the company’s discount rate, revenue growth, profit margin and future P/E profile. Analyst Commentary Bearish analysts cutting the price target to €26 are signaling a more cautious stance on Stratec’s risk and reward trade off at current levels.Anlatı Güncellemesi • Feb 08
SBS: Future Upside Will Rely On Earnings Power And Cost Controls
Narrative update on Stratec Analysts have trimmed their 12 month price target on Stratec by about €1, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent research updates on Stratec point to a small pullback in published price targets, with a reduction of about €1 in the latest move and a prior cut from €30 to €27.Anlatı Güncellemesi • Jan 23
SBS: Future Margin Recovery Will Rely On Efficiency Gains And Cost Controls
Analysts have trimmed their price target on Stratec, with the average moving slightly lower in line with a recent cut from €30 to €27, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. Analyst Commentary Recent research points to a more cautious stance on Stratec, with the reduced €27 price target reflecting updated views on what analysts see as fair value, the applied discount rate, revenue growth assumptions, margin profile and future P/E expectations.Analiz Makalesi • Jan 10
Returns On Capital Signal Tricky Times Ahead For Stratec (ETR:SBS)
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...Anlatı Güncellemesi • Jan 08
SBS: Index Exit And 2025 Margin Guidance Will Define Upside Potential
Analysts have trimmed their fair value estimate for Stratec from about €51.00 to roughly €44.96. This aligns with a recent reduction in the Street price target to €27 from €30 as they factor in updated assumptions on discount rates, revenue growth, profit margins, and future P/E multiples.Anlatı Güncellemesi • Dec 18
SBS: Margin Recovery Outlook Will Support Upside Despite Reduced Price Objective
Analysts have trimmed their price target on Stratec to EUR 27.00 from EUR 30.00, reflecting slightly more cautious assumptions on long term growth, a higher discount rate, and a modestly lower future P E multiple, despite marginally improved margin expectations. Analyst Commentary Bearish analysts have highlighted that the reduction in the price target to EUR 27.00 signals a more guarded stance on Stratec's medium to long term prospects, even as the rating on the shares remains unchanged at Hold.Anlatı Güncellemesi • Dec 04
SBS: Future Margin Gains Will Emerge As Cost Controls Take Hold
Analysts have modestly reduced their price target on Stratec, trimming it by EUR 3 to EUR 27. This reflects slightly lower long term return expectations while maintaining a cautious stance on the shares.Analiz Makalesi • Nov 29
Stratec (ETR:SBS) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Anlatı Güncellemesi • Nov 20
SBS: Margins Will Improve With Cost Management And Leadership Changes
The analyst price target for Stratec has been revised downward from €30 to €27. Analysts cited a slightly higher discount rate and modest changes in growth and profitability expectations as key drivers behind the adjustment.Analiz Makalesi • Nov 11
Stratec SE (ETR:SBS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Stratec SE ( ETR:SBS ) shareholders are probably feeling a little disappointed, since its shares fell 5.2% to €21.75 in...Analiz Makalesi • Nov 07
Investors Give Stratec SE (ETR:SBS) Shares A 35% Hiding
Stratec SE ( ETR:SBS ) shares have had a horrible month, losing 35% after a relatively good period beforehand. The drop...Anlatı Güncellemesi • Nov 03
SBS: Future Leadership Will Drive Healthcare Diagnostics Forward Amidst Margin Pressures
Analysts have revised their price target for Stratec downward from €36.58 to €33.30, citing expectations of slower revenue growth and a slight decrease in profit margins. What's in the News Tanja Bücherl will join STRATEC SE's Board of Management as Chief Financial Officer effective November 1, 2025.Analiz Makalesi • Sep 23
Getting In Cheap On Stratec SE (ETR:SBS) Might Be Difficult
Stratec SE's ( ETR:SBS ) price-to-earnings (or "P/E") ratio of 25.3x might make it look like a sell right now compared...Anlatı Güncellemesi • Aug 23
Automation And Digitalization Will Transform Healthcare Diagnostics
Stratec’s consensus price target has been revised downward, primarily reflecting lowered forecasts for both revenue growth and net profit margin, resulting in a new fair value of €37.32. What's in the News Stratec increased its dividend to €0.60 per share for 2024 (previously €0.55), totaling €7.3 million to be distributed.Analiz Makalesi • Jun 17
An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 34% Undervalued
Key Insights Stratec's estimated fair value is €36.05 based on 2 Stage Free Cash Flow to Equity Stratec is estimated to...Analiz Makalesi • Apr 25
Why We're Not Concerned About Stratec SE's (ETR:SBS) Share Price
With a price-to-earnings (or "P/E") ratio of 30.8x Stratec SE ( ETR:SBS ) may be sending very bearish signals at the...
Yeni Anlatı • Feb 09
Efficiency Measures And Acquisitions Like Natech Will Boost Future Market Presence
Efficiency measures and cost discipline initiatives could enhance net margins as market conditions stabilize.Analiz Makalesi • Jan 18
An Intrinsic Calculation For Stratec SE (ETR:SBS) Suggests It's 42% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Stratec fair value estimate is €55.10 Stratec's €32.10 share...Analiz Makalesi • Nov 09
With A 25% Price Drop For Stratec SE (ETR:SBS) You'll Still Get What You Pay For
Stratec SE ( ETR:SBS ) shares have had a horrible month, losing 25% after a relatively good period beforehand. The drop...Analiz Makalesi • Oct 26
Returns At Stratec (ETR:SBS) Appear To Be Weighed Down
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analiz Makalesi • May 11
Here's Why It's Unlikely That Stratec SE's (ETR:SBS) CEO Will See A Pay Rise This Year
Key Insights Stratec to hold its Annual General Meeting on 17th of May Total pay for CEO Marcus Wolfinger includes...Analiz Makalesi • Apr 11
Stratec's (ETR:SBS) Dividend Will Be Reduced To €0.55
Stratec SE's ( ETR:SBS ) dividend is being reduced from last year's payment covering the same period to €0.55 on the...Analiz Makalesi • Apr 01
Stratec SE Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Stratec SE ( ETR:SBS ) filed its yearly result this time last week. The early...Analiz Makalesi • Mar 28
Stratec (ETR:SBS) Has Announced That Its Dividend Will Be Reduced To €0.55
The board of Stratec SE ( ETR:SBS ) has announced it will be reducing its dividend by 43% from last year's payment of...Analiz Makalesi • Dec 21
Is There An Opportunity With Stratec SE's (ETR:SBS) 36% Undervaluation?
Key Insights Stratec's estimated fair value is €67.40 based on 2 Stage Free Cash Flow to Equity Stratec's €43.00 share...Analiz Makalesi • Nov 03
Slowing Rates Of Return At Stratec (ETR:SBS) Leave Little Room For Excitement
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analiz Makalesi • Oct 19
We Think Stratec (ETR:SBS) Is Taking Some Risk With Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Jul 12
Return Trends At Stratec (ETR:SBS) Aren't Appealing
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Analiz Makalesi • Jun 27
Stratec SE (ETR:SBS) Shares Could Be 43% Below Their Intrinsic Value Estimate
Key Insights Stratec's estimated fair value is €110 based on 2 Stage Free Cash Flow to Equity Stratec is estimated to...Analiz Makalesi • May 25
Is Stratec (ETR:SBS) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Hissedar Getirileri
| SBS | DE Medical Equipment | DE Pazar | |
|---|---|---|---|
| 7D | 2.9% | 2.6% | 3.2% |
| 1Y | -34.6% | -27.3% | 2.5% |
Getiri vs. Endüstri: SBS geçen yıl % -27.3 oranında getiri sağlayan German Medical Equipment sektörünün gerisinde kaldı.
Getiri vs Piyasa: SBS geçen yıl % 2.5 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| SBS volatility | |
|---|---|
| SBS Average Weekly Movement | 6.1% |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 13.6% |
| 10% least volatile stocks in DE Market | 2.7% |
İstikrarlı Hisse Senedi Fiyatı: SBS son 3 ayda German piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: SBS 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1979 | 1,343 | Marcus Wolfinger | www.stratec.com |
Stratec SE, iştirakleriyle birlikte Almanya, Avrupa Birliği ve uluslararası alanda in-vitro diagnostik ve yaşam bilimleri alanlarında otomasyon ve enstrümantasyon çözümleri tasarlamakta ve üretmektedir. Klinik tanı ve biyoteknoloji müşterileri için otomatik analizör sistemleri tasarlar ve üretir; ve tanı ve tıbbi uygulamalar için karmaşık sarf malzemeleri sunar. Şirket daha önce STRATEC Biomedical AG olarak biliniyordu ve Aralık 2018'de adını Stratec SE olarak değiştirdi.
Stratec SE Temel Bilgiler Özeti
| SBS temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | €209.57m |
| Kazançlar(TTM) | -€3.40m |
| Gelir(TTM) | €243.93m |
0.9x
P/S Oranı-61.6x
F/K OranıSBS aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| SBS gelir tablosu (TTM) | |
|---|---|
| Gelir | €243.93m |
| Gelir Maliyeti | €185.54m |
| Brüt Kâr | €58.38m |
| Diğer Giderler | €61.78m |
| Kazançlar | -€3.40m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 14, 2026
| Hisse başına kazanç (EPS) | -0.28 |
| Brüt Marj | 23.93% |
| Net Kâr Marjı | -1.39% |
| Borç/Özkaynak Oranı | 0% |
SBS uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
3.5%
Mevcut Temettü Verimi-3,014%
Ödeme OranıSBS güvenilir bir temettü ödüyor mu?
SBS temettü geçmişine ve kıyaslamalara bakın| Stratec temettü tari̇hleri̇ | |
|---|---|
| Eski Temettü Tarihi | Jun 24 2026 |
| Temettü Ödeme Tarihi | Jun 26 2026 |
| Eski temettüye kadar geçen günler | 32 days |
| Temettü ödeme tarihine kadar geçen günler | 34 days |
SBS güvenilir bir temettü ödüyor mu?
SBS temettü geçmişine ve kıyaslamalara bakınŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 05:50 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Stratec SE 11 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Heider | Berenberg |
| Jan Koch | Deutsche Bank |
| Jan Koch | Deutsche Bank |